The magnitude of survival benefit and biomarker support makes this a strong catalyst for partnership interest or accelerated development. Traders should monitor for upcoming FDA interactions, trial expansion plans, or financing needs given the company's limited cash runway into July 2026.
Price Chart
Executive Summary
Actuate Therapeutics announced positive Phase 2 trial results for elraglusib in metastatic pancreatic cancer, showing a 2.9-month improvement in median overall survival (10.1 vs 7.2 months) and a 38% reduction in risk of death. The data, published in Nature Medicine, demonstrate clinically meaningful survival benefits and immunomodulatory effects, supporting further development of elraglusib as a first-line combination therapy.
Key Facts
- Phase 2 trial showed median overall survival of 10.1 months with elraglusib + GnP vs 7.2 months with GnP alone
- 38% reduction in risk of death (HR 0.62; p=0.01)
- 1-year survival rate doubled to 44.1% vs 22.3% in control arm
- Results published in peer-reviewed journal Nature Medicine
- Company has not yet initiated pivotal trials or filed for approval; drug remains investigational
Financial Impact
High potential long-term value given unmet need in pancreatic cancer, though near-term dilution risk exists due to going-concern uncertainty
Risk Factors
- Requires additional capital beyond July 2026; going concern uncertainty remains
- Phase 3 trial not yet initiated; regulatory approval not guaranteed
- Toxicity profile includes higher rates of Grade ≥3 neutropenia and fatigue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3273413 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | S-1/A | $0.5990 $0.5279 | ▲ +11.87% | ▲ +11.72% | $0.5280 (+11.85%) |
Oct 14, 2026 12d ago | S-1/A | $0.4342 $0.5622 | ▼ −29.48% | ▼ −29.03% | $0.5280 (−21.60%) |
Oct 6, 2026 20d ago | S-1 | $0.7240 $0.4340 | ▲ +40.06% | ▲ +39.07% | $0.5280 (+27.07%) |
Aug 12, 2026 10w ago | Institutional Cluster | $0.9699 $1.06 | ▼ −9.29% | ▼ −9.73% | $0.5280 (+45.56%) |
Jun 9, 2026 19w ago | Press Release | $2.01 $2.05 | ▲ +1.99% | ▼ −0.42% | $0.5280 (−73.73%) |
May 11, 2026 24w ago | 8-K | $2.89 $2.43 | ▼ −15.92% | ▼ −15.99% | $0.5280 (−81.73%) |
May 6, 2026 24w ago | DEFA14A | $2.99 $2.89 | ▼ −3.34% | ▼ −4.48% | $0.5280 (−82.34%) |
May 6, 2026 24w ago | 8-K | $2.99 $2.89 | ▼ −3.34% | ▼ −4.48% | $0.5280 (−82.34%) |
Apr 14, 2026 27w ago | Press Release | $2.08 $2.27 | ▲ +8.89% | ▲ +7.50% | $0.5280 (−74.62%) |
Mar 9, 2026 33w ago | Press Release | $2.95 $2.68 | ▼ −9.00% | ▼ −7.64% | $0.5280 (−82.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers